Limpa 10 mg+5 mg (Tablet)

Unit Price: ৳ 35.00 (3 x 10: ৳ 1,050.00)
Strip Price: ৳ 350.00

Medicine Details

Category Details
Generic Empagliflozin linagliptin
Company Aristopharma ltd
Also available as
Limpa 25 mg tablet

Title

  • Limpa - Type 2 Diabetes Medication

Categories

  • Diabetes Medication
  • Metabolic Disorders
  • Pharmacology
  • Therapeutic Class: SGLT2 Inhibitors

Description

  • Adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus
  • Inhibits DPP-4 enzyme, increasing active incretin hormones
  • Stimulates insulin release in a glucose-dependent manner
  • Reduces levels of glucagon and hepatic glucose output
  • Inhibits Sodium-glucose co-transporter 2 (SGLT2), increasing urinary glucose excretion
  • Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily, morning, with or without food
  • Increased dose: 25 mg Empagliflozin and 5 mg Linagliptin once daily
  • Contraindicated in severe renal impairment, hypersensitivity reactions, history of serious hypersensitivity reaction to Empagliflozin
  • Not recommended during second and third trimesters of pregnancy
  • Precautions for pancreatitis, hypotension, ketoacidosis, acute kidney injury, urosepsis, hypoglycemia, genital mycotic infections, hypersensitivity, heart failure
  • Storage conditions: Store below 30°C, away from light and wet place, keep out of reach of children

Dimensions

  • N/A

Color Options

  • N/A

Functions

  • Improves glycemic control
  • Stimulates insulin release
  • Reduces glucagon levels
  • Increases urinary glucose excretion

Materials

  • N/A

Technical Specifications

  • Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily
  • Increased dose: 25 mg Empagliflozin and 5 mg Linagliptin once daily

Design Elements

  • N/A

Usability Features

  • Adjunct to diet and exercise
  • Morning administration
  • Can be taken with or without food

Dosage Administration

  • Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily, morning, with or without food
  • Increased dose: 25 mg Empagliflozin and 5 mg Linagliptin once daily
  • Renal function assessment before initiating the tablet
  • Discontinue if eGFR falls below 45 ml/min/1.73 m²

Interaction

  • Coadministration with diuretics may increase urine volume and frequency of voids
  • Coadministration with Insulin or Insulin secretagogues increases risk for hypoglycemia
  • Rifampin decreases Linagliptin exposure
  • SGLT2 inhibitors increase urinary glucose excretion
  • Interferes with 1,5-anhydroglucitol (1,5-AG) assay
  • Inducers of P-glycoprotein or CYP3A4 enzymes may reduce efficacy

Contraindications

  • Severe renal impairment, end-stage renal disease, or dialysis
  • History of hypersensitivity reaction to Linagliptin or Empagliflozin
  • Serious hypersensitivity reaction to Empagliflozin

Side Effects

  • Pancreatitis
  • Ketoacidosis
  • Volume depletion
  • Urosepsis and Pyelonephritis
  • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
  • Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene)
  • Genital Mycotic Infections
  • Hypersensitivity Reactions
  • Severe and Disabling Arthralgia
  • Bullous Pemphigoid
  • Heart Failure

Pregnancy & Lactation

  • Not recommended during second and third trimesters of pregnancy
  • Limited available data in pregnant women
  • Risks associated with poorly controlled diabetes in pregnancy

Precautions & Warnings

  • Precaution in conditions like pancreatitis, hypotension, ketoacidosis, acute kidney injury, urosepsis, hypoglycemia, genital mycotic infections, hypersensitivity
  • Reports of acute pancreatitis and fatal pancreatitis
  • Reports of ketoacidosis, including fatal cases
  • Can cause symptomatic hypotension or acute transient changes in creatinine
  • Increased risk for urinary tract infections
  • Increased risk for genital mycotic infections
  • Association with heart failure observed in cardiovascular outcomes trials

Overdose Effects

  • Contact Poison Control Center
  • Employ usual supportive measures
  • Removal of Empagliflozin by hemodialysis not studied
  • Removal of Linagliptin by hemodialysis or peritoneal dialysis unlikely

Therapeutic Class

  • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

  • Below 30°C temperature
  • Keep away from light and wet place
  • Keep out of reach of children

Related Brands